Treating anemia associated with chronic renal failure with erythropoiesis stimulators: Recombinant human erythropoietin might be the best among the available choices

Trkulja, Vladimir

doi:10.1016/j.mehy.2011.10.016

Cited by 2 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EPO is a hypoxia-induced hormone produced by the kidney and fetal liver which can stimulate hematopoiesis in the bone marrow. Since obtained Food and Drug Administration (FDA) license for clinical use, EPO and its analogs rHu-EPO have been used for treatment of the anemias caused by chronic renal failure, malignancies and proved to be effective [22,23]. In recent years, EPO has captured the attention of surgeons for its excellent efficacy in improving perioperative anemia caused by massive blood loss [24].…”

Section: Discussionmentioning

confidence: 99%

Does subcutaneous administration of recombinant human erythropoietin increase thrombotic events in total hip arthroplasty? A prospective thrombelastography analysis

et al. 2020

View full text Add to dashboard Cite

Background Anemia is one of severe complications in the perioperative period of total hip arthroplasty (THA). Erythropoietin (EPO) has been considered to improve patients’ anemia state, but its efficiency and safety remains controversial. Methods A total of 152 patients who underwent total hip arthroplasty from January 2017 to March 2019 were randomized to 2 groups. Recombinant human erythropoietin (rHu-EPO) group was treated with rHu-EPO subcutaneous injection 10000 IU after operation and once daily in the next week, while control group was treated with none extra treatment. Routine hematologic examination and thrombelastography (TEG) performed at different time point respectively. Doppler ultrasound for bilateral lower limbs was performed 1 day before surgery and 7 days after surgery. Auxiliary examination outcomes, blood transfusions outcomes, and postoperative complications were recorded as assessment indicators. Results The difference in the relevant indexes of traditional coagulation and TEG values between two groups were not significantly. No significant difference was observed in the incidence of thromboembolism events and other complications between two groups during postoperative period. The amount of intraoperative blood loss was similar between the two groups. However, the postoperative use and dosage of allogeneic blood in the rHu-EPO group were lower than those in the control group. The hemoglobin and hematocrit level in the rHu-EPO group were higher than that in the control group after surgery. Conclusion Postoperative subcutaneous injection of rHu-EPO can improve hematological anemia-related parameters, reduce the use and dosage of allogeneic blood transfusions (ABTs), and has no significant influence on the formation of thrombosis and other complications in patients undergoing total hip arthroplasty in short term.

show abstract

Section: Discussionmentioning

confidence: 99%

Does subcutaneous administration of recombinant human erythropoietin increase thrombotic events in total hip arthroplasty? A prospective thrombelastography analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Treatment options are limited in women with CRF. Erythropoietin is prohibitively expensive and unaffordable for many patients [9]. Information is not available on the pharmacokinetics of any of the progestins for use in chronic renal disease [10].…”

Section: Discussionmentioning

confidence: 99%

Radiofrequency endometrial ablation for treating heavy menstrual bleeding in women with chronic renal failure

Jiang

Xue

2018

International Journal of Hyperthermia

View full text Add to dashboard Cite

Objective: The study objective was to retrospectively evaluate the efficacy and safety of radiofrequency endometrial ablation in treating heavy menstrual bleeding (HMB) in women with chronic renal failure (CRF). Method: Fifty-eight patients with CRF undergoing radiofrequency endometrial ablation in our hospital between January 2013 and July 2017 and for whom complete follow-up data were available were included. Outcome measures included amenorrhea, treatment failure and operative complications. Results: The mean patient age was 41.4 ± 7.7 years, the mean preoperative hemoglobin level was 69.6 ± 19.3 g/dL, the mean preoperative serum creatinine level was 879.1 ± 415.4 mmol/L, and the mean urea level was 18.2 ± 7.1 mmol/L. The mean treatment time for radiofrequency endometrial ablation was 61.7 ± 18.8 s. The median volume of estimated blood loss during the procedure was 10 mL (a range of 2-50 mL). On average, the study subjects were monitored for 24.4 months (a range of 6-60 months). The average amenorrhea rate was 89.7%. Only 2 (3.4%) patients required additional gynecologic surgery after endometrial ablation. Intra-and postoperative complications were not observed. Conclusion: Radiofrequency endometrial ablation was demonstrated to be safe and effective for the treatment of HMB in women with CRF.

show abstract

Treating anemia associated with chronic renal failure with erythropoiesis stimulators: Recombinant human erythropoietin might be the best among the available choices

Cited by 2 publications

References 29 publications

Does subcutaneous administration of recombinant human erythropoietin increase thrombotic events in total hip arthroplasty? A prospective thrombelastography analysis

Does subcutaneous administration of recombinant human erythropoietin increase thrombotic events in total hip arthroplasty? A prospective thrombelastography analysis

Radiofrequency endometrial ablation for treating heavy menstrual bleeding in women with chronic renal failure

Contact Info

Product

Resources

About